Clinical trials: Erlotinib
Carcinoma, Non-Small-Cell Lung
LUX-Lung 8: A Phase III Trial of Afatinib (BIBW 2992) Versus Erlotinib for the Treatment of Squamous Cell Lung Cancer After at Least One Prior Platinum Based Chemotherapy
This randomised, open-label phase III trial will be performed in patients with advanced squamous cell carcinoma of the lung requiring second-line treatment after receiving first-line platinum-based chemotherapy.
- Trial name
- NCT01523587
- Testing
- afatinib, erlotinib
- Where
- 192 sites in United States, Argentina and 21 more
- Volunteers
- 795 people
- Sponsor
- Boehringer Ingelheim
Renal Cell Carcinoma, Metastases
A Study Evaluating Tarceva in Combination With Avastin Versus Avastin Alone in Treating Metastatic Renal Cell Carcinoma
The primary purpose of the study is to assess the potential benefit of combining two targeted therapies (an anti-EGF inhibitor along with an anti-VEGF inhibitor).
- Trial name
- NCT00081614
- Testing
- Avastin (bevacizumab), Tarceva (erlotinib HCl)
- Where
- 20 sites in United States
- Volunteers
- 100 people
- Sponsor
- Genentech, Inc.
Non-small Cell Lung Cancer, EGFR Gene Mutation
First Line Treatment in EGFR Mutation Positive Advanced NSCLC Patients With Central Nervous System (CNS) Metastases
The first-line treatment with single agent AZD3759 results in superior Progression Free Survival (PFS) compared to Standard of Care (SoC) Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors (EGFR-TKI), in patients with…
- Conditions
- Non-small Cell Lung Cancer, EGFR Gene Mutation, Brain Metastases
- Trial name
- BM (NCT03653546)
- Testing
- AZD3759, Erlotinib, Gefitinib
- Where
- 58 sites in China, Singapore and 2 more
- Volunteers
- 492 people
- Sponsor
- Alpha Biopharma (Jiangsu) Co., Ltd.
Non Small Cell Lung Cancer
A Study of Abemaciclib (LY2835219) in Participants With Previously Treated KRAS Mutated Lung Cancer
The main purpose of this study is to evaluate how safe and effective the study drug known as abemaciclib is in participants with lung cancer.
- Trial name
- JUNIPER (NCT02152631)
- Testing
- Abemaciclib, Erlotinib
- Where
- 231 sites in United States, Argentina and 19 more
- Volunteers
- 453 people
- Sponsor
- Eli Lilly and Company